|
Market Closed -
Oslo Bors
10:45:00 2026-09-29 EDT
|
5-day change | 1st Jan Change | ||
| 3.590 NOK | -0.55% |
|
-10.92% | +48.84% |
| 08-28 | Nykode Therapeutics Raises NOK286 Million via Share Placement | MT |
| 08-27 | ABG Sundal Collier raises the target price for Nykode Therapeutics to 7.0 Norwegian kroner (4.5), reiterates buy | FW |
Company Valuation: Nykode Therapeutics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 23,372 | 8,287 | 6,988 | 994.7 | 787.6 | 1,179 | - | - |
| Change | - | -64.54% | -15.67% | -85.77% | -20.81% | 49.67% | - | - |
| Enterprise Value (EV) 1 | 21,490 | 6,164 | 5,327 | -251.9 | 236.2 | 690.2 | 544.7 | 661.5 |
| Change | - | -71.32% | -13.58% | -104.73% | 193.76% | 192.18% | -21.09% | 21.44% |
| P/E | -307x | -18.1x | -16.8x | -2.28x | -6.31x | -5.49x | 68.8x | -15.4x |
| PBR | - | 5.11x | 3.85x | 0.66x | 0.9x | 1.79x | 1.48x | 1.75x |
| PEG | - | -0x | 0.9x | -0.44x | 0.1x | -0.1x | -1x | 0x |
| Capitalization / Revenue | 74.5x | 88.8x | 49.5x | 9.75x | 182x | - | 5.52x | 14.6x |
| EV / Revenue | 68.5x | 66.1x | 37.8x | -2.47x | 54.6x | - | 2.55x | 8.19x |
| EV / EBITDA | -244x | -11.4x | -8.99x | 0.49x | -0.93x | -2.58x | -17.8x | -4.42x |
| EV / EBIT | -228x | -11.2x | -8.66x | 0.47x | -0.87x | -2.54x | -15.5x | -4.57x |
| EV / FCF | 8,641x | -25.5x | -5.11x | 0.44x | -0.84x | -4.82x | -143x | -4.92x |
| FCF Yield | 0.01% | -3.92% | -19.6% | 227% | -119% | -20.7% | -0.7% | -20.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2627 | -1.55 | -1.271 | -1.336 | -0.382 | -0.657 | 0.0525 | -0.235 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 313.5 | 93.31 | 141.1 | 102 | 4.326 | - | 213.7 | 80.73 |
| EBITDA 1 | -87.93 | -542.7 | -592.6 | -513.1 | -253.5 | -267.5 | -30.67 | -149.5 |
| EBIT 1 | -94.36 | -549.3 | -615.1 | -538.1 | -273 | -271.8 | -35.16 | -144.8 |
| Net income 1 | -82.32 | -441.7 | -372.3 | -432.2 | -116.9 | -211.4 | 11.3 | -89.2 |
| Net Debt 1 | -1,882 | -2,123 | -1,661 | -1,247 | -551.4 | -488.6 | -634.1 | -517.3 |
| Reference price 2 | 80.700 | 28.120 | 21.400 | 3.046 | 2.412 | 3.610 | 3.610 | 3.610 |
| Nbr of stocks (in thousands) | 289,619 | 294,694 | 326,546 | 326,546 | 326,546 | 326,546 | - | - |
| Announcement Date | 3/31/22 | 2/28/23 | 2/28/24 | 2/26/25 | 2/25/26 | - | - | - |
1NOK in Million2NOK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.49x | - | -2.58x | - | 124M | |
| 21.02x | 7.45x | 14.97x | 1.41% | 71.81B | |
| 31.2x | 8.99x | 28.02x | 0.04% | 60.06B | |
| 32.35x | 6.9x | 17.92x | -.--% | 27.93B | |
| -72.02x | 13.86x | -70.68x | -.--% | 25.7B | |
| -15.29x | 5.82x | -7.32x | -.--% | 24.89B | |
| 28.77x | 5.41x | 17.98x | -.--% | 20.92B | |
| 42.74x | 15.97x | 32.4x | 0.35% | 15.04B | |
| 18.03x | 5.37x | 12.55x | -.--% | 14.46B | |
| 990.12x | 34.59x | 597.44x | -.--% | 13.87B | |
| Average | 107.14x | 11.60x | 64.07x | 0.2% | 27.48B | |
| Weighted average by Cap. | 62.93x | 9.76x | 38.54x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VACC Stock
- Valuation Nykode Therapeutics
Select your edition
All financial news and data tailored to specific country editions
